Elixinol Builds Personalised Wellness Platform with Vitable Acquisition

Vitable Adds Subscription Scale to Elixinol

Elixinol Wellness Limited (ASX:EXL) is buying personalised supplement platform Vitable in a deal designed to take the company past A$20 million in annual revenue while adding a recurring direct-to-consumer channel. Vitable brings approximately 7,850 active subscribers, proprietary recommendation technology and 1.84 million completed customer health assessments.

The headline consideration is A$2.5 million, payable entirely in Elixinol shares, with most of the value deferred or tied to performance. If the earn-out conditions are fully realised, the combined group is targeting A$27 million in revenue and approximately A$3 million in EBITDA by 2028. Those figures are targets rather than guidance, and depend on the acquisition completing and Vitable meeting the specified performance hurdles.

Deferred Shares Limit Upfront Cash Exposure

The structure gives Elixinol an immediate A$312,500 in shares on completion, followed by another A$312,500 six months later and A$625,000 at the 12-month mark. A further A$625,000 may be issued after 12 months and another A$625,000 after 24 months, with those tranches measured against net revenue and direct EBITDA.

At the minimum issue price of A$0.00525, the headline consideration could require as many as 476.2 million new shares. The arrangement therefore avoids an upfront cash payment but does not make the transaction costless for existing shareholders. A separate A$1 million Platform Kicker is available if Elixinol's 20-trading-day VWAP-implied market capitalisation exceeds A$20 million within 36 months of completion.

Personalisation Becomes the Strategic Bet

Vitable gives Elixinol a subscription relationship that sits alongside its existing food, nutrition and wellness brands. Management has identified cross-selling opportunities, including introducing The Healthy Chef products to Vitable customers and offering Vitable's personalised supplements to Elixinol's established customer base. The announcement also flags potential future testing-led services, although at-home testing remains subject to partner, regulatory and clinical review.

Vitable shareholder Ben McHarg, who co-founded Life-Space Group before its sale to BY-HEALTH, and other Vitable shareholders have committed A$500,000 to Elixinol through a convertible note, subject to shareholder approval. That commitment would align the incoming shareholders with the combined company's performance, but it does not remove the execution challenge of integrating a subscription platform without disrupting its customer base.

Shareholder Vote Stands Between Deal and Completion

Completion remains conditional on Elixinol shareholder approval, further due diligence, the absence of a material adverse change, any required third-party consents and other conditions in the definitive agreement. The company expects to hold the approval meeting in early November and has applied to ASX for a waiver allowing deferred consideration shares to be issued on the proposed schedule.

The attraction is clear: a relatively small acquisition could add recurring revenue, proprietary customer data and a digital route to market. The harder test will be whether Vitable's subscriber base converts into durable revenue and EBITDA while the share count expands. The next decisive evidence will come from the meeting materials, the ASX waiver outcome and the first operating figures after completion.